These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27977433)

  • 1. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
    Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
    Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.
    Aspeslagh S; Awada A; S Matos-Pita A; Aftimos P; Bahleda R; Varga A; Soria JC
    Anticancer Drugs; 2016 Nov; 27(10):1021-7. PubMed ID: 27610894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.
    Salazar R; Plummer R; Oaknin A; Robinson A; Pardo B; Soto-Matos A; Yovine A; Szyldergemajn S; Calvert AH
    Invest New Drugs; 2011 Dec; 29(6):1406-13. PubMed ID: 20623160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
    Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
    Krege S; Rexer H; vom Dorp F; de Geeter P; Klotz T; Retz M; Heidenreich A; Kühn M; Kamradt J; Feyerabend S; Wülfing C; Zastrow S; Albers P; Hakenberg O; Roigas J; Fenner M; Heinzer H; Schrader M
    BJU Int; 2014 Mar; 113(3):429-36. PubMed ID: 24053564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
    Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
    Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
    Mateos MV; Cibeira MT; Richardson PG; Prosper F; Oriol A; de la Rubia J; Lahuerta JJ; García-Sanz R; Extremera S; Szyldergemajn S; Corrado C; Singer H; Mitsiades CS; Anderson KC; Bladé J; San Miguel J
    Clin Cancer Res; 2010 Jun; 16(12):3260-9. PubMed ID: 20530693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
    Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
    Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
    Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
    Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
    Naqi N; Ahmad S; Murad S; Khattak J
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Aspeslagh S; Shailubhai K; Bahleda R; Gazzah A; Varga A; Hollebecque A; Massard C; Spreafico A; Reni M; Soria JC
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1257-1265. PubMed ID: 28424962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
    Goldwasser F; Faivre S; Alexandre J; Coronado C; Fernández-García EM; Kahatt CM; Paramio PG; Dios JL; Miguel-Lillo B; Raymond E
    Invest New Drugs; 2014 Jun; 32(3):500-9. PubMed ID: 24395456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.